Education
About Us
Working with TipRanks
Follow Us
Biotron Limited (AU:BIT)
ASX:BIT
BIT Stock Chart & Stats
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.03
Previous CloseN/A
Volume463.29K
Average Volume (3M)1.60M
Market Cap
$3.32M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,327,245,800
10 Day Avg. Volume3,265,462
30 Day Avg. Volume1,601,469
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biotron News
BIT FAQ
What was Biotron Limited’s price range in the past 12 months?
Biotron Limited lowest share price was <AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Biotron Limited’s market cap?
Biotron Limited’s market cap is $3.32M.
When is Biotron Limited’s upcoming earnings report date?
Biotron Limited’s upcoming earnings report date is Aug 29, 2025 which is in 30 days.
How were Biotron Limited’s earnings last quarter?
Currently, no data Available
Is Biotron Limited overvalued?
According to Wall Street analysts Biotron Limited’s price is currently Overvalued.
Does Biotron Limited pay dividends?
Biotron Limited does not currently pay dividends.
What is Biotron Limited’s EPS estimate?
Biotron Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotron Limited have?
Biotron Limited has 1,327,245,800 shares outstanding.
What happened to Biotron Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biotron Limited?
Currently, no hedge funds are holding shares in AU:BIT
Biotron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BIT Sentiment 82%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
-44.44%
12-Months-Change
Fundamentals
Return on Equity
-119.28%
Trailing 12-Months
Asset Growth
-65.03%
Trailing 12-Months
Company Description
Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
Biotron (BIT) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Vectus Biosystems Limited
―
Regeneus Ltd.
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Ownership Overview
2.89%
Insiders
―
Mutual Funds
― Other Institutional Investors
97.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---